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Abstract:  With the progress of cancer, the macromolecules such as DNA, RNA, lipids, etc. inside cells 
undergo spatial structural rearrangements and alterations. Mesoscopic physics based optical partial wave 
spectroscopy (PWS) was recently introduced to quantify changes in the nanoscale structural disorder in 
biological cells. The measurement is done in a parameter termed as ‘disorder strength’ (Ld) which 
represents the degree of nanoscale structural disorder inside the cells. It was shown that cancerous cells 
have higher disorder strength than the normal cells. In this work, using the PWS technique, we analyzed 
the hierarchy of different types of prostate cancer cells by quantifying their average disorder strengths. 
The results showed that increase in the tumorigenicity level of prostate cancer is correlated with the 
increase in the disorder strength Ld.  Furthermore, using the Ld parameter we also analyzed docetaxel 
chemo-resistance attribute of these prostate cancer cells, in comparison to docetaxel chemo-sensitive 
cancer cells. Our results show that chemo drug resistive cancer cells have mutations to more aggressive, 
or increased in Ld values relative to the chemo sensitive cancer cells. Potential applications of the Ld 
parameter for determining the effectiveness of the chemotherapy drug on cancer cells are discussed. 
  Keywords: optical media, disorder strength, prostate cancer, docetaxel, chemo-resistance, spectroscopy. 
 
1    Introduction 
1.1  Role of nanoscale mass density fluctuations in detection of cancer  
 It is now known that the progress of cancer is associated with the nanoscale intracellular 
structural alteration is cells/tissues.
1.2
 Based on an interdisciplinary approach combining 
mesoscopic physics and biophotonics, optical partial wave spectroscopic microscopy (PWS) was 
introduced earlier to quantify the nanoscale structural disorder in weakly disordered optical 
media, such as biological cells.
3,4  
PWS approach has shown efficiency in cancer diagnostics 
5-7
.  
From then, there are different versions of the PWS has been developed, with the same goal of 
measuring nanoscale structural alteration in cells
8,9
. In this work, we have used a newly 
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developed PWS instrument featuring finer focus that provides an accurate scattering volume 
elements.  PWS analysis is based on statistical quantification of the backscattered spectral or 
back reflected intensities, and their spectral correlation decay length due to the nanoscale 
refractive index fluctuation within biological samples. Finer focus for reflection volume allows 
accurate reflection of focus depth vertically, and for compute optical disorder. In PWS technique, 
a thin sample can be divided into several parallel scattering samples, or the bulk backscattering 
problem can be approximated as quasi one dimensional scattering problem. The reflection in 
each channel or sub-sample provides two parameters: rms of the reflection spectra and the 
correlation of the reflection spectra. From these two quantities, the effective structural disorder 
or nanoscale “disorder strength Ld” was characterized within biological cells (briefly shown in 
the later section). Where Ld =<dn
2
>×lc, <dn
2
>
1/2
 is the strength of the refractive index 
fluctuations related to the mass density fluctuations in the cell, and  lc is the spatial correlation 
decay length of the spatial refractive index fluctuations
9,3,4
. In this paper, we study the 
effectiveness of chemotherapy drug on cancer treatment using cancer cell lines. In particular, 
using prostate cancer cell lines, we have shown that the intracellular structural characteristics of 
the chemotherapy drug action on human prostate cancer cells of different cell lines. In particular, 
we examined the intracellular structural properties of the drug-resistive or drug-sensitive cells, of 
these cell lines. The effectiveness of drug action or drug-resistance can be evaluated using the 
cells’ intracellular structural optical disorder strength parameter Ld  value, this parameter acts as 
a potential biomarker for effectiveness of drug action characterization as will be shown in our 
results. Our results show that the drug resistive cancer cells have different structural disorder or 
disorder strength Ld value than the usual cancer (control) cells. From the earlier experimental 
results on cancer cell studies, we already know that increased in structural disorder strength 
correlated with the increased in the aggressiveness or more tumorigenicity, and the decreased in 
disorder strength were related to the less aggressiveness or less tumorigenicity state of the cell.
3-6
  
Therefore, these results suggest that  drug-non-resistive and drug-resistive cancer cells are 
different in their structural disorder. These nanoscale alterations are in turn related to the  
nanoscale mass density fluctuations or nanoscale refractive index fluctuations.  Therefore, the 
strength or the degree of disorder strength, Ld, in terms of optical scattering can be considered as 
a potential biomarker, whose values can provide the effectiveness of chemotherapy drug 
treatment, that is to differentiate between non-drug-resistive and drug-resistive cases of cancer 
cells. 
          In the following sections, we have described the PWS experiments with prostate cancer 
cell lines, chemotherapy drug-non-resistive and  drug-resistive cells, description of the developed 
PWS instruments with finer focus, and the PWS experimental results of drug-non-resistive and 
drug-resistive cancer cells. 
1.2 Prostate cancer and effect of chemotherapy drug 
Prostate cancer is most commonly diagnosed among  men and often metastasizing at later ages. 
It was known that 161,360 new cases were predicted in the United States for 2016 including 
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26,730 cases of death
9
. It is estimated to almost 19% cause of cancer mortality in the USA. One 
in seven men gets prostate cancer in their lifetime. Prostate cancer is prominent in the older men, 
60% man above the age 66 diagnosed with prostate cancer, 1 in 39 men in America dies in 
prostate cancer, and it is the 3
rd
 leading cause of death in the United States.
9
 Therefore, effective 
detection and treatment of prostate cancer are important, especially for seniors.  Chemotherapy is 
used to treat metastasized prostate cancer.. However, chemotherapy is often ineffective because 
cells of individual patients’ tumors develop chemo-resistance.11-13 Hence, it is important to know 
the effectiveness of the chemotherapy drug for the treatment and assess the resistance in the 
prostate cancer for better affective treatment and development of the new treatment drugs. 
1.3 Prostate cancer treatment and role of chemotherapy:   
 Prostate cancer treatment usually includes steps of three types: radiation, surgery, and 
chemotherapy. These treatment types are performed in distinct orders according to the stage and 
size of the malignant tumor. Usually, chemotherapy administered after surgery to remove the 
tumor and prostate; this therapy expects to kill the metastasized cancer cells around the prostate 
gland as well as in the whole body. Resistance to chemotherapy is one of the main cause of 
treatment failure in all types of cancer treatment, including that of prostate cancer. Development 
of drug resistance by cancer cells is a serious problem since it ends the remission stage and leads 
to disease relapse. Clinically, chemotherapy drug docetaxel (Taxotere®) is frequently used to 
treat the advanced stages (metastasis) of prostate cancer.
 However, the prostate cancer cell’s 
resistance to this drug is a major clinical problem because it was established as the primary drug 
therapy for metastatic prostate cancer 
13
.  Docetaxel resistance is correlated with the time period 
over which the cancer cells were/are treated with the drug and the dosages used.
14
 Researchers 
are studying the drug resistance and are trying to understand the physiological effect of other 
chemotherapeutic drugs that can bypass the resistance and restore near-normal growth and 
division processes for the cells remaining after chemotherapy.
15,16,17
 
 In this study, we will assess the docetaxel resistance through the use of in vitro human 
prostate cancer cell line model: C4-2, DU-145 and PC3, where the individual cell line was 
treated with a dose of the docetaxel up to a period of 8 months using a standard protocol. In 
different  chemo-resistance studies, the aggressiveness and invasion of the resistive cancer cells 
has been observed
21,22
. In addition, it has been reported that the docetaxel resistance in a cancer 
cell is highly associated with genetic alterations
16
..These genetic mutations lead to the 
rearrangement and alteration of the most basic building blocks of the cells, such as DNAs, RNAs 
and Lipids, in turn produce intracellular structural changes at the nanoscale in the treated cancer 
cells that can be detected by the conventional microscopy imaging
20
. Here, the effect of the drug 
on the change of the intra-cellular nano-architecture is measured through an established 
parameter called  degree of structural disorder or disorder strength Ld (=<dn
2
>×lc) as defined 
earlier, and compared to the corresponding values for non-drug treated cancer cells. The results 
reveal that chemo-resistant cells show a different value of mean disorder strength Ld for the all 
the above three cell lines compared to their corresponding wild type cancer cells. The results 
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support the hypothesis that the prostate cancer cells acquire docetaxel chemo-resistance and 
ultimately showed no response towards docetaxel treatments. Here we are establishing the fact 
that the disorder strength  Ld  is an efficient parameter or biomarker that can characterize usual 
prostate cancer cell-lines and drug-resisted cancer cells using partial wave spectroscopy  PWS or 
spectroscopic microscopy method. 
 To establish the fact that Ld  is a potential parameter  or biomarker, we first established the 
hierarchy of the normal and prostate cancer cell lines. Then we have treated the chemotherapy 
drug to establish the differences in structural disorder between the drug-non-resistance and drug-
resistance cancer cells. 
2    Method 
2.1 Cell culture and development of docetaxel chemo-resistant prostate cancer cells of the 
following cell lines: C4-2 (PSMA+), DU145 (PSMA−) and PC-3 (PSMA−) 
      Prostate Cancer (PCa) cell lines [C4-2 (PSMA+), DU145 (PSMA−) and PC-3 
(PSMA−)] were developed in cell culture facilities at the University of Tennessee Health Science 
Center (UTHSC), and cultured in RPMI-1640 medium containing 10% (v/v) fetal bovine serum 
(FBS), and 2 mM L-glutamine (Invitrogen, Carlsbad, CA) and 1% (w/v) penicillin–streptomycin 
(Gibco, Thermo Fisher Scientific, Grand Island, NY) at 37 °C in a humidified 5% CO2–95% air 
atmosphere (Thermo Fisher Scientific, Waltham, USA). PCa resistant lines were generated by 
initial treatments with docetaxel (MP Biomedicals, Santa Ana, CA) at 1 nM (from 5 µM stock) 
in 75 cm2 flasks for 24-48 hours. After treatment, the surviving cells were re-seeded into new 
flasks and allowed to recover for 1-2 days. Cells were maintained at 1 nM till 4 treatment cycles 
(4 TC). Gradually the concentration of docetaxel was increased to 2.5nm (6 TC). Further, the 5 
ad 10 nM of Dtxl was continued till 8 and 12 TC, respectively.  Then all cells underwent 12 TC 
and 15 TC with Dtxl 15 ad 20 nM, respectively. Finally, at 30 nM Dtxl we have performed 25 
TC, to ensure the acquisition of chemo-resistance in all C4-2, DU145, and PC-3 cells. Following 
each treatment, cells were allowed to fully recuperate before assessing their resistance to 
docetaxel and any experimental work.
3
 Since the passage number of the drug treated cells 
increased over time, a subset of PCa cells were aged alongside these cells as an appropriate 
control to ensure that the effects seen were due to resistance rather than due to an ageing effect of 
the PCa cells. 
2.2 Cell imaging and analysis 
  Frozen cell batches with similar passages were thawed and used for all experiments. For image 
analysis studies, we have seeded 2.5 × 10
4
 in each well of 4- chambered slides (Sarstedt. Inc, 
Newton, NC) and allowed to grow. Cells after reaching 70-80% of confluence, they were fixed 
using 4% para-formaldehyde for 20 mins.  After incubation cells were washed with PBS and 
cells were imaged, analyzed 
17, 18, 19
. 
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3     Optical partial wave spectroscopy (PWS) experiment 
3.1   Instrumentation  
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1  Experimental setup for partial wave microscopy spectroscopy (PWS).  A broad band light is focused on a 
beam splitter and passes through a microscopy objective and reflected back from the sample.  The backscattered 
light from the sample  is focused onto a LCTF coupled with a CCD camera.  
 
 
A schematic of experimental apparatus used for partial wave spectroscopic microscopy is shown 
in figure 1. This PWS setup is the version developed at the University of Memphis that provide 
finer focus.   A broadband of white light from a Xenon Lamp (Thor Lab) is used to illuminate 
the sample using the technique of Kohler illumination. First the light directed through a 
broadband dielectric round mirror (dimeter=50mm, R>99%, thickness=12.7mm ) to pass through 
a set of  lenses (convex, f=50mm) and apertures to collimate the light as shown in the Fig. 1. 
Then the light is reflected  by a right angle prism (BRP, 25.mm) to let it pass through a beam 
splitter plate (BSP, 50:50) to a low numerical aperture objective (NA=0.65, 40x). Then, the beam  
focused on the sample which is kept on electronic motorized stage (Zaber Tech Inc.) with precise 
resolutions of 100nm vertical (z-direction) and 40 nm in x-y plane and so that the depth of the 
image was focused more accurately that from the previous versions
3,4
. This element provided the 
control on the accurate depth of focus in turn the reflection from the sample. The backscattered 
light passes through the objective again and is projected into a liquid crystal tunable filter 
(LCTF) (Verispace, LLC) where the signal is filtered according to its wavelength components. 
The spectral resolution of the LCTF is 1nm. The spectral range is the visible range (450-700nm). 
L4 
BRP 
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The filtered signal is captured by the CCD camera detector (Cool Snap, LLC), which is coupled 
to the LCTF. 
 
3.2 Derivation of value of Ld from backscattering intensity  
 
    The CCD camera detect and store the backscattered image of the biological cell at every 
wavelength (λ) in the visible range, 450nm -700nm. Each image is represented by a matrix with 
(x,y) the spatial position within the matrix, and each matrix element is captured at one 
wavelength (λ) at a time. Eventually, we acquire a cube data from the PWS system I(x,y;λ) and 
further processing for the data, we extract the backscatter spectrum fluctuation  R( x,y λ).  Imaged  
cells were quite thin (~1 µm) while lying on glass slides, therefore, the  backscattered intensities 
could be decomposed using a simultaneous parallel backscattering channel assumption for the 
back reflection. In addition, the back-reflection data could be analyzed based on the mesoscopic 
physics framework. In this assumption Ld was derived from the two quantities, the RMS value of 
the reflection intensity <R>rms  and the spectral correlation decay of the reflection intensity 
C(Δk), as described in our earlier publications.3,4   It can be shown that: 
 
 
constant and )( kC   is where B is the normalization 
the autocorrelation function of R(x,y,k) at a particular position (x,y) and averaged over many 
ensembles. The acquisition time for each cell is ~1 min. The data were collected, and the average 
of  Ld was calculated for each point (x,y). It can be further shown that. 
       2~d cL dn l  . 
where <dn
2
> is the variance of the refractive index and  lc is the spatial correlation length of the   
refractivity index fluctuation of an optical sample.3,4 
 
4    Results and Discussions 
         To demonstrate the ability of the present PWS instrument to identify nano-architectural 
changes in cells with different levels of tumorigenicity and modifications of these tumorigenicity 
level due to the induced drug resistance of the cells by drug exposure, we performed our first set 
of experiments on different prostate human adenocarcinoma cell lines. We focused on the 
prostate cancer given that it is a major public health problem in the United States. Moreover, 
chemotherapy-induced drug resistance is an observable clinical problem. We chose three prostate 
cancer cell lines with already known extents of tumorigenicity, low, moderate, and very high, 
which were, DU145, C4-2 and PC3 respectively.  PWS structural disorder measurements were 
conducted on ~ 20 cells randomly selected from each cell type for one single measurement (~60 
cells for all 3 cells types). Subsequently, mesoscopic physics based analysis of the backscattered 
data matrix R(λ, x, y) was performed on the sets of data for each cell type.   
2
2
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Fig. 2  Representative bright field images (a,b,c)  and corresponding  2D Ld maps (a’,b’,c’) (PWS images) for the 
three prostate cell line DU145, C4-2, PC3,1,2,3 respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3  The bar plots of  mean intracellular disorder strength Ld  calculated for three types of human prostate cancer 
cells (DU145, C4-2, PC3).  The Ld results show that the average Ld  value correlate with the tumorigenicity level of 
the cell. 
 
     In Fig. 2, we have extracted the reflectance part R(λ,x,y) and its correlation length to 
calculate the disorder strength Ld  parameter for each pixel of CCD in the captured  PWS images, 
as described in the method. The Ld  value was calculated for each pixel in the individual cell 
image and represented by plot of 2D color maps, and named as an PWS  Ld map.  In Figs. 2 (a)-
(c), three representative bright field image of each cell line is presented, and the corresponding 
PWS Ld maps are shown in Figs. 2(a’)-(c’). The bright filed images, as shown in (a), (b), and (c) 
of the three types of cells appear not differentiable, however corresponding Ld  maps, as shown 
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in figures (a’), (b’), and (c’) that are clearly different. The red spots are corresponding to the 
higher disorder strength, of higher Ld value of that pixel.  
    For statistical comparison, the corresponding bars in graph of Fig. 3 shows the average Ld 
from 20 cells from each type of cell line and the corresponding error bars represent the standard 
error of the mean. In Fig. 3, significant statistical differences in the local disorder strength Ld 
values are visually obvious according to the number of red regions displayed for the three-
distinct prostate cancer cell lines. Clearly, the fraction of higher Ld values increased in the more 
aggressive cancer cells. Importantly, the most aggressive cell line (PC3) has the highest 
intercellular disorder strength, while the least aggressive cell line (Du145) exhibited the least 
structural disorder or disorder strength. These results suggest higher disorder strength is 
associated with an increase in the tumorigenicity level in the cell. 
     In the next step, we assessed the structural effects that may introduced on the prostate 
cancer cells from the three-cell lines due to the prolonged, hopefully therapeutic treatment with 
the chemotherapy drug  docetaxel. We hypothesized that prostate cancer cell lines may develop 
some type of resistance to the drug after a prolong time of treatment (8 months in this case), and 
that this behavior would be associated with additional intracellular structural changes as well.   
          In particular, an imprint of structural disorder in the drug resistive prostate cancer cells 
was expected.  To test our hypothesis, we performed PWS measurement on docetaxel treated 
cells of cell lines PC3, C4-2, and DU145, as well as on corresponding age matched cell lines. 
These tests may answer the question if the drug-resistant cells showed measurable structural 
changes associated with the aggressiveness behavior that prostate cancer cells acquired after 8 
months of docetaxel chemotherapy drug treatment. 
           Using image collection and value extraction as described above, we first observed the 
disorder strength for the docetaxol-treated cells (resistance cells are noted by R) from each type 
of prostate cancer cell line, and compared the Ld parameter calculated for the drug treated cells 
with the Ld calculated for cancer cells in the first set of the experiment by considering the later as  
wild (non-resistive to drug) cancer cells. In Fig. 4, we have plotted the 2D Ld maps for the three 
representative resistance cell lines and for the corresponding control (cancer) cells. The maps use 
a color bar from blue to red to show an increasing value of the disorder strength Ld value.  Clear 
differences are visible in the PWS Ld   maps for the control and the resistance cell for each type of  
cells individually representing the three types of cells lines; whereas, in contrast to that display,  
the bright field images of these cells types look quite similar and definite features are difficult to 
quantify. Most interestingly, the 2D maps of Ld of  the resistance cells showed higher values of  
Ld  compared to the control cells and they were consistent for the three type of  the prostate 
cancer cell lines. 
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Fig. 4 (a-f) Bright field images of three types of human prostate cell line:  (control) and its corresponding (resistance 
R) cells from the same cell type.  (a’-f’).  The colored images are the PWS images, a 2D map of Ld, images show the 
representative mean intracellular disorder strength between the control and the corresponding drug resistance 
prostate cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5   Bar plots for mean intracellular disorder strength value Ld calculated for  three types of human prostate 
cancer cells from cell lines:  (a)  C3,  (b) C4-2, and (c) DU-145) (control vector), and  compared with the mean 
intercellular disorder strength of the  corresponding  cancer cells treated with docetaxel  drug for about 8 months. 
The drug resistive survival cells are called  drug resistance cells ( noted by R : drug resistance). It can be seen that 
the each drug resistance cell type has higher Ld   than its corresponding control/wild type. 
 
 
        To further show that the structural differences between the control and the drug-resistance 
cells, in Fig. 5, we plotted the bar graphs for mean Ld values for the control and the resistant  
cells averaged over 20 cells for each cell type. These data are shown in Fig.5, where the mean Ld  
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value is significantly elevated in the drug-resistant cells that were induced with docetaxel, as 
compared with the untreated cells.  
    The results not only show the cancer cells underwent changes in their nanoarchitecture 
associated with the prolonged exposure to the chemotherapy drug, but also show the potential 
use and quantitative capacity of the disorder strength, Ld, as a parameter or biomarker for 
accessing structural changes measured at the nanoscale in the cancerous cells, that are associated 
with drug-exposure resistance. 
 
5     Conclusions  
             In summary, we have shown the application of partial wave spectroscopy as developed 
in the present apparatus to demonstrate readily detectable differences in cells at selected stages of 
prostate cancer. The stages were selected because they represent levels of tumorigenicity for 
prostate cancer cells, and accordingly the measurements are likely to have clinical utility. Human 
prostate cancer cell line samples, the control cells (or non-drug-exposed cells) and corresponding 
cells exhibiting drug-resistance linked to prior exposure to the chemotherapy drug docetaxel, 
showed a significant difference in their degree of structural disorder strength Ld values. Cancer 
cells were treated with docetaxel, the mean disorder strength of the cells that survived drug 
exposure was higher as shown by Ld values compare to the Ld  value of the control (docetaxel 
chemo-sensitive cells) samples for all three cell types: PC3, C4-2 and DU-145. 
  The results suggest that there are different structural alterations have happened in the 
structures of the prostate cells for control (non-drug-resistance cancer cells) and drug-resistive 
cancer cells.  These alterations presented as a structural alteration or mass-density fluctuations 
increases in survival cells when the drug is introduced and used for a long period. 
 The drug-resistant cells had greater ranges of structure than the drug-sensitive cells and 
this is reflected in their intracellular structural disorder properties, or disorder strength.  There are 
different mechanism for cancerous cells going for drug resistance. Such as: drug inactivation, 
alteration of drug targets, DNA damage repair, cell death inhibition, epithelial-mesenchymal 
transition and metastasis, cancer cell heterogeneity, cancer cell heterogeneity etc,.
23-26
  As the 
drug resistive cells are surviving more due to the different pathways of the drug resistance to the 
cancer cells as few are listed above, the cancer cells increase their aggressiveness, in turn 
increase in the structural disorder due to random growth. And this extra increase in the structural 
disorder in drug resistive cancer cells can be measured  and shown to be a potential biomarker to 
access the effect of chemotherapy drug. 
           These experimental results provided a new insight to the chemotherapy drug-resistance 
cells and associated increased in the structural disorder. The origin of these extra structural 
changes and their correlations with the specific molecular changes, and importantly how these 
structural changes are related to the drug resistance, are yet to be explored in details. Yet, when 
they are, the local value of Ld can be matched to the submicroscopic details. 
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